J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More
Executive Summary
Daily round-up of news and notes from the 2017 J.P. Morgan Healthcare conference in San Francisco. Bristol-Myers CEO humbled by PD-1 competition in lung cancer; Sanofi’s sarilumab manufacturing issues resolved; Biogen, Ionis discuss SMA drug’s high cost; Shire happy with Xiidra launch to date; Sarepta says more than 250 patients have started Exondys treatment; J&J’s Gorsky on innovation and pricing; and Amicus reveals US approval strategy for migalastat.
You may also be interested in...
Keeping Track: US FDA Approves Emflaza And Parsabiv, Turns Down Opioid/Anti-Emetic Combo CL-108
The latest drug development news and highlights from our FDA Performance Tracker.
Ionis: Another Shot At The Commercial Market And Sustainable Profits
Spinraza, launched by partner Biogen, is the antisense developer’s newest drug to reach the market. Ionis plans to file its first wholly-owned drug, volanesorsen, later this year.
Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review
EMA and payers want to know more about daily life improvements from US FDA-approved Duchenne muscular dystrophy treatment.